DiaSorin

What DiaSorin does

DiaSorin S.p.A. is an Italian multinational in vitro diagnostics (IVD) company founded in 1968 and headquartered in Saluggia, Italy, publicly listed on Borsa Italiana (FTSE MIB, ticker DIA). The company develops, manufactures, and sells diagnostic products through three operating segments: immunodiagnostics anchored by the LIAISON platform family (LIAISON XL, LIAISON XS), molecular diagnostics using Simplexa Real-Time PCR, VERIGENE NanoGrid, and xTAG/NxTAG technologies, and Licensed Technology via the Luminex xMAP bead-based multiplexing platform acquired in 2021 for approximately $1.8 billion. DiaSorin serves hospitals, blood banks, reference laboratories, and research/life sciences customers across more than 100 countries, with named enterprise relationships including Quest Diagnostics and distribution partnerships with McKesson. The product portfolio spans automated high-throughput immunochemistry analyzers, point-of-care molecular platforms (LIAISON NES), syndromic molecular panels, specialty assays (LIAISON QuantiFERON TB-Gold Plus, LIAISON MeMed BV, Simplexa C. auris), and the Luminex microsphere reagent and instrumentation business.

DiaSorin operates a razor-and-blade commercial model: over 80% of revenue derives from high-margin reagents and consumables used on its installed base of instruments, with the remainder from upfront instrument/system sales and Luminex technology licensing. The company sells through direct enterprise field sales to hospital and laboratory networks, supplemented by strategic distribution partnerships for point-of-care and reference-lab channels, and a Luminex partner ecosystem offering commercial immunoassay kits. Geographic exposure spans Europe, North America, and Asia Pacific including Japan and China. Pricing is quote-based under multi-year enterprise contracts and not publicly disclosed.

FY 2025 financial performance was €1.195 billion in revenue (+1% YoY, with 5% core business growth offset by FX and China headwinds), net profit of €150 million (-20% YoY), approximately 75% gross margin, and 34.3% EBITDA margin. Management guides to 5-6% revenue growth and 32-33% adjusted EBITDA margin in FY 2026, with a 6-8% CAGR projected through 2030 and approximately €1 billion in cumulative free cash flow between 2027 and 2030. Recent strategic moves include FDA 510(k) clearance and CLIA waiver for the LIAISON NES respiratory panel (Dec 2025), an FDA de novo for the Simplexa C. auris Direct assay (Jan 2025), supply and distribution agreements with Quest Diagnostics and McKesson, a QIAGEN/Inpeco partnership for automated TB workflows (May 2026), a Shanghai plant restructuring, CFO transition, and appointment of a new Immuno Division President.

Name

DiaSorin

Legal name

DiaSorin S.p.A.

Website

https://diasorin.com

Company type

Public

Founded year

1968

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

DiaSorin is an Italian in vitro diagnostics company serving hospitals, blood banks, and reference labs in 100+ countries with LIAISON immunochemistry systems, Simplexa/VERIGENE molecular diagnostics, and Luminex xMAP multiplexing platforms, generating ~80% of revenue from recurring reagent and consumable sales.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

Keywords

• In vitro diagnostics
• Immunodiagnostics
• Molecular diagnostics
• Diagnostic reagents
• Clinical diagnostics

Headquarters

HQ city

Saluggia

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Reagent and Consumable Sales: Over 80% of sales come from reagents and consumables used in LIAISON immunochemistry systems and molecular diagnostics platforms, providing recurring revenue with high-margin consumables attached to installed instrument base
2. Instrument/System Sales: Sale of diagnostic instruments including LIAISON XL, LIAISON XS, LIAISON MDX, and Luminex systems, generating upfront revenue with ongoing consumable attachment
3. Luminex Technology Licensing: Licensed Technology sector providing xMAP Technology platforms, microspheres, and associated reagents to research and clinical diagnostic customers

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

DiaSorin develops, manufactures, and commercializes in vitro diagnostic (IVD) test kits and instruments for immunodiagnostics and molecular diagnostics. Its products are used by hospitals, blood banks, reference laboratories, and research institutes for clinical diagnostics and research applications.

Product overview

DiaSorin is a world leader in laboratory diagnostics specializing in immunodiagnostics and molecular diagnostics segments, with a third segment in Licensed Technology through its Luminex acquisition. The product portfolio centers on the LIAISON platform family (LIAISON XL, LIAISON XS for immunodiagnostics; LIAISON MDX, LIAISON NES, LIAISON PLEX for molecular diagnostics) which deliver automated testing for infectious diseases, gastrointestinal diseases, hepatitis, endocrinology, metabolic disorders, and tumor markers. The Luminex segment provides the xMAP Technology platform comprising instruments (xMAP INTELLIFLEX, FLEXMAP 3D, Luminex 200, MAGPIX), microsphere reagents (MicroPlex, MagPlex variants, SeroMAP), and xPONENT software for bead-based multiplexing up to 500 targets. Consumables (assays, reagents, microspheres) constitute over 80% of sales, providing a recurring revenue model built on the installed instrument base.

Differentiator

Problem solved

Functional benefit

Brands

• LIAISON: Immunochemistry and molecular diagnostics platform including LIAISON XL, LIAISON XS, LIAISON MDX, LIAISON NES, and LIAISON PLEX systems
• Simplexa
• VERIGENE
• Luminex
• xTAG

Products and services

• LIAISON platform

Quantifiable outcome

• Core business growth of 5% despite overall revenue growth of 1% due to currency headwinds
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• QIAGENcoreTechnology or Integration · 7 May 2026QIAGEN partnership with Diasorin for LIAISON systems integration in automated QuantiFERON latent TB testing workflow. QIAGEN is developing a fully automated Sample to Insight workflow for its QuantiFERON-TB Gold Plus test targeting late 2027, integrating with Diasorin's LIAISON detection systems and Inpeco's laboratory automation to reduce hands-on time by up to 80%.
• InpecocoreStrategic or Co-development Partner · 7 May 2026Inpeco partnered with QIAGEN and Diasorin to provide laboratory automation for the automated Sample to Insight workflow for QuantiFERON latent TB testing, enabling laboratories to decouple volume growth from staffing requirements.
• McKessonminorChannel Partner/ Reseller/ Distributor · 19 March 2026Distribution deal with McKesson for point-of-care molecular diagnostics system targeting decentralized testing settings, expanding Diasorin's reach in point-of-care markets.
• Quest DiagnosticscoreChannel Partner/ Reseller/ Distributor · 22 October 2025Diasorin signed agreement to supply 24 Liaison Plex molecular testing systems to Quest Diagnostics US labs, a major laboratory services provider, representing significant placement of molecular diagnostics instruments.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• QIAGEN: German molecular diagnostics and sample technologies company with QuantiFERON TB franchise and QIAstat-Dx syndromic testing platform. Now a DiaSorin integration partner for TB workflow automation, but also a peer in molecular diagnostics infectious disease testing serving similar hospital lab customers.
• Hologic: US diagnostics and medical technology company with molecular diagnostics franchise (Panther system, Aptima assays) overlapping DiaSorin's Simplexa and VERIGENE molecular offerings. Comparable in specialty IVD positioning and reagent-heavy recurring model, with stronger women's health and screening menu.
• bioMérieux: French in vitro diagnostics specialist with similar scope in clinical microbiology, immunoassays, and molecular diagnostics. Closely comparable to DiaSorin in business model (reagent-heavy, ~80% consumables, hospital/lab customer base), specialty focus versus IVD majors, and European heritage.
• QuidelOrtho: US-based specialty diagnostics company formed from the merger of Quidel and Ortho Clinical Diagnostics, focused on immunoassays, molecular diagnostics, and rapid testing. Comparable to DiaSorin in specialty IVD positioning and reagent-heavy revenue mix, though smaller scale.
• Bio-Rad Laboratories: US-based life science and clinical diagnostics company with overlapping offerings in clinical chemistry, immunology (including its own immunoassay systems), quality controls, and life science research reagents. Comparable to DiaSorin in IVD reagent manufacturing and life science tools overlap from the Luminex segment.

Broad incumbents

• Roche Diagnostics: Division of Roche that is the global IVD market leader across immunodiagnostics (cobas), molecular diagnostics, clinical chemistry, and tissue diagnostics. Overlaps directly with DiaSorin's LIAISON (immunodiagnostics) and Simplexa/VERIGENE (molecular) franchises but operates at much larger scale with broader menu and central lab dominance.
• Siemens Healthineers: Major diagnostics player operating the Atellica and ADVIA Centaur immunoassay/clinical chemistry platforms, competing in the same hospital lab segment as DiaSorin's LIAISON franchise. Broader portfolio spans imaging and therapy but the diagnostics unit is a direct large-scale IVD competitor.
• Revvity: Former PerkinElmer life sciences and diagnostics business, providing immunodiagnostics, molecular diagnostics reagents, and life science instruments. Overlaps with DiaSorin in clinical IVD reagents and with the Luminex legacy in research reagents and instruments.
• Danaher (Beckman Coulter, Cepheid, Radiometer): Diversified life sciences conglomerate whose diagnostics subsidiaries (Beckman Coulter for immunodiagnostics/chemistry, Cepheid for molecular GeneXpert, Radiometer for blood gas) compete across DiaSorin's full IVD portfolio. Significant scale, broader menu, and stronger point-of-care molecular presence via Cepheid.
• Abbott Diagnostics: Major IVD franchise within Abbott covering immunoassays (ARCHITECT), molecular diagnostics (Alinity m), point-of-care, and rapid diagnostics. Direct competitor to DiaSorin in immunochemistry and molecular testing, with broader menu and stronger point-of-care presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCzE7zzL-Qyb5x9bK6sWEW2g
• LinkedInlinkedin.com/company/diasorin
• Xx.com/diasoringroup

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DiaSorin